Serological Markers As Prognostic Criteria for the Course of HIV Infection

Overview

Journal Infection

Date 1991 Jan 1

PMID 1901833

Authors

A Kleinschmidt

A Matuschke

F D Goebel

V Erfle

R Hehlmann

Affiliations

Soon will be listed here.

Abstract

576 serum samples from 139 HIV infected patients were analyzed for the presence of HIV antigens, as well as anti-core, anti-env and neutralizing antibodies. The results were correlated with the clinical and immunological stages of the patients. While almost all sera were positive for anti-env antibodies, only two thirds of the same sera had antibodies to core proteins. The average antibody titres, particularly of anti-core antibodies, decreased with the onset of clinical symptoms. The presence of p24 antigen could be demonstrated in only 16% of the sera. A positive reaction for core antigen seemed to be correlated with the absence of anti-core antibodies. Env specific neutralizing antibodies were found to be present in all of the sera analyzed in the LC5-test with a maximum neutralizing capacity observed in sera from WR 4 patients. A useful serological marker must fulfil two criteria, namely positive reactivity in the majority of sera examined and a broad range of antibody titres. None of the above described parameters meet these demands. Here we describe the search for new antibody markers, for example antibodies directed against HIV regulatory proteins.

References

Lange J, de Wolf F, Goudsmit J . Markers for progression in HIV infection. AIDS. 1989; 3 Suppl 1:S153-60. DOI: 10.1097/00002030-198901001-00023. View

Mellert W, Kleinschmidt A, Schmidt J, Festl H, Emler S, Roth W . Infection of human fibroblasts and osteoblast-like cells with HIV-1. AIDS. 1990; 4(6):527-35. DOI: 10.1097/00002030-199006000-00006. View

Reiss P, de Ronde A, Lange J, de Wolf F, Dekker J, Danner S . Low antigenicity of HIV-1 rev: rev-specific antibody response of limited value as correlate of rev gene expression and disease progression. AIDS Res Hum Retroviruses. 1989; 5(6):621-8. DOI: 10.1089/aid.1989.5.621. View

Reiss P, de Ronde A, Lange J, de Wolf F, Dekker J, Debouck C . Antibody response to the viral negative factor (nef) in HIV-1 infection: a correlate of levels of HIV-1 expression. AIDS. 1989; 3(4):227-33. DOI: 10.1097/00002030-198904000-00006. View

Dewhurst S, Embretson J, Anderson D, Mullins J, Fultz P . Sequence analysis and acute pathogenicity of molecularly cloned SIVSMM-PBj14. Nature. 1990; 345(6276):636-40. DOI: 10.1038/345636a0. View

Prince A, Pascual D, Kosolapov L, Kurokawa D, Baker L, Rubinstein P . Prevalence, clinical significance, and strain specificity of neutralizing antibody to the human immunodeficiency virus. J Infect Dis. 1987; 156(2):268-72. DOI: 10.1093/infdis/156.2.268. View

Ranki A, Weiss S, Valle S, Antonen J, Krohn K . Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins. Clin Exp Immunol. 1987; 69(2):231-9. PMC: 1542406. View

Weber J, Clapham P, Weiss R, Parker D, Roberts C, Duncan J . Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis. Lancet. 1987; 1(8525):119-22. DOI: 10.1016/s0140-6736(87)91964-7. View

Franchini G, Robert-Guroff M, Wong-Staal F, Ghrayeb J, Kato I, Chang T . Expression of the protein encoded by the 3' open reading frame of human T-cell lymphotropic virus type III in bacteria: demonstration of its immunoreactivity with human sera. Proc Natl Acad Sci U S A. 1986; 83(14):5282-5. PMC: 323935. DOI: 10.1073/pnas.83.14.5282. View

10.

Falk Jr L, Paul D, Landay A, Kessler H . HIV isolation from plasma of HIV-infected persons. N Engl J Med. 1987; 316(24):1547-8. DOI: 10.1056/NEJM198706113162413. View

11.

Wieland U, Kuhn J, Jassoy C, Rubsamen-Waigmann H, Wolber V, Braun R . Antibodies to recombinant HIV-1 vif, tat, and nef proteins in human sera. Med Microbiol Immunol. 1990; 179(1):1-11. DOI: 10.1007/BF00190145. View

12.

Allan J, Coligan J, Lee T, McLane M, Kanki P, Groopman J . A new HTLV-III/LAV encoded antigen detected by antibodies from AIDS patients. Science. 1985; 230(4727):810-3. DOI: 10.1126/science.2997921. View

13.

Wendler I, Bienzle U, Hunsmann G . Neutralizing antibodies and the course of HIV-induced disease. AIDS Res Hum Retroviruses. 1987; 3(2):157-63. DOI: 10.1089/aid.1987.3.157. View

14.

Schneider T, Hildebrandt P, Ronspeck W, Weigelt W, Pauli G . The antibody response to the HIV-1 specific "out" (vpu) protein: identification of an immunodominant epitope and correlation of antibody detectability to clinical stages. AIDS Res Hum Retroviruses. 1990; 6(7):943-50. DOI: 10.1089/aid.1990.6.943. View

15.

Ameisen J, Guy B, Chamaret S, Loche M, Mouton Y, Neyrinck J . Antibodies to the nef protein and to nef peptides in HIV-1-infected seronegative individuals. AIDS Res Hum Retroviruses. 1989; 5(3):279-91. DOI: 10.1089/aid.1989.5.279. View

16.

Robert-Guroff M, Goedert J, Naugle C, Jennings A, Blattner W, Gallo R . Spectrum of HIV-1 neutralizing antibodies in a cohort of homosexual men: results of a 6 year prospective study. AIDS Res Hum Retroviruses. 1988; 4(5):343-50. DOI: 10.1089/aid.1988.4.343. View